Company IDEAYA Biosciences, Inc.

Equities

IDYA

US45166A1025

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
43.88 USD +1.32% Intraday chart for IDEAYA Biosciences, Inc. -3.84% +23.33%

Business Summary

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.

Number of employees: 124

Sales per Business

USD in Million2022Weight2023Weight Delta
Oncology-focused Precision Medicine
100.0 %
51 100.0 % 23 100.0 % -54.08%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
51 100.0 % 23 100.0 % -54.08%

Managers

Managers TitleAgeSince
Founder 49 15-05-31
Director of Finance/CFO 38 16-07-31
Chief Tech/Sci/R&D Officer - 21-10-31
Chief Tech/Sci/R&D Officer - 19-06-30
Chief Tech/Sci/R&D Officer - 22-11-20
Corporate Officer/Principal - 17-12-31
General Counsel 53 19-09-30

Members of the board

Members of the board TitleAgeSince
Director/Board Member 64 16-05-05
Director/Board Member 68 19-12-16
Director/Board Member 68 22-04-04
Founder 49 15-05-31
Director/Board Member 69 15-09-30
Director/Board Member 69 21-02-16
Director/Board Member 58 20-06-25
Director/Board Member 66 18-06-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 74,560,273 73,827,925 ( 99.02 %) 0 99.02 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
6.943 %
5,116,525 6.943 % 229 M $
Federated MDTA LLC
5.270 %
3,883,775 5.270 % 174 M $
T. Rowe Price International Ltd.
4.839 %
3,566,278 4.839 % 159 M $
Janus Henderson Investors US LLC
4.820 %
3,551,891 4.820 % 159 M $
Vanguard Fiduciary Trust Co.
4.716 %
3,475,772 4.716 % 155 M $
2,991,899 4.060 % 134 M $
Adage Capital Partners GP LLC
3.969 %
2,925,094 3.969 % 131 M $
Deerfield Management Co. LP (Private Equity)
3.569 %
2,630,292 3.569 % 118 M $
Boxer Capital LLC
2.989 %
2,202,812 2.989 % 98 M $
Capital Research & Management Co. (Global Investors)
2.683 %
1,976,870 2.683 % 88 M $

Company contact information

IDEAYA Biosciences, Inc.

7000 Shoreline Court Suite 350

94080-1945, South San Francisco

+650 443 6209

http://www.ideayabio.com
address IDEAYA Biosciences, Inc.(IDYA)